{
  "abstract": "In Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), 81% of patients respond well to at least one of the established first-line therapies: corticosteroids, immunoglobulin or plasma exchange (PLEX).1 2 However, studies comparing their efficacy and tolerability are limited. Nobile-Orazio et al showed response at 6 months to either pulsed intravenous methylprednisolone (IVMP) or intravenous immunoglobulin (IVIg) was equivalent, but improvement was seen earlier with IVIg (6 weeks vs 3 months with IVMP).3 Importantly, none of the IVMP responders relapsed on discontinuation but almost 40% of IVIg responders required ongoing regular infusions to maintain response.3",
  "authors": [
    {
      "affiliations": [
        "Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Manchester, UK"
      ],
      "name": "Ryan Yann Shern Keh"
    },
    {
      "affiliations": [
        "Centre for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery, London, UK",
        "UCL Queen Square Institute of Neurology, London, UK"
      ],
      "name": "Aisling S Carr"
    }
  ],
  "title": "Steroids or immunoglobulin for CIDP first-line treatment: why not both?",
  "uid": "29822000-38dc-5c92-b051-203a6e02fe80"
}